Catalyst Event

Moderna Inc (MRNA) · Other

From KEDI U.S. Quality500 + Monthly 1% Premium Index(NTR) (KUSQL500P)

8/5/2026, 12:00:00 AM

OtherSentiment: Neutral

The U.S. FDA has a PDUFA target action date of August 5, 2026, for a decision on Moderna's seasonal flu vaccine candidate, mRNA-1010, scheduled. This major regulatory decision is estimated to have a high price impact (>10%), scheduled.

Korean Translation

2026년 8월 5일로 예정된 FDA의 계절성 독감 백신 mRNA-1010 승인 결정이 10% 이상의 주가 변동을 일으킬 것으로 예정됨.

Related Recent Events

View Full Timeline